High expression of exogenous cDNAs directed by HIV-1 long terminal repeat in human cells constitutively producing HIV-1 tat and adenovirus E1A/E1B.
A eukaryotic vector-host cell system is described where the additive transactivating effects of HIV-1 tat and adenovirus E1A on HIV-1 long terminal repeat (LTR) are exploited to increase expression of exogenous cDNAs. Human 143B and 293 cells, the latter constitutively producing E1A, were used as host cell lines. The bacterial gene chloramphenicol acetyltransferase (CAT) and the hepatitis B surface antigen (HBs-Ag) gene were employed as reporter genes inserted in pRPneoU3R, an episomal vector containing BK virus replication origin and early region, where cDNAs are expressed under control of HIV-1 LTR. The 293 cells were transformed by tat expression vectors to constitutively express tat. Stable cell clones of 293tat cells, constitutively expressing CAT after transformation with pRPneoU3R-CAT, show a CAT activity 600-fold higher than normal 293 transformed cells. CAT expression obtained in normal 293 cells can be transiently increased 10-fold by transfection by vectors expressing tat. The 293tat cells transformed by pRPneoU3R-HBs, an episomal vector expressing HBs-Ag from HIV LTR, yielded stable cell clones secreting HBs-Ag in the culture medium at a concentration up to 744 ng/ml or 44 ng/10(6) cells/24 h, 48-fold more than normal 293 cells. The use of this system for constitutive or inducible expression of sequences under control of HIV-1 LTR is discussed in view of possible applications for diagnostic, vaccinal and therapeutic purposes.
Negrini
M
M
University of Ferrara, School of Medicine.
Rimessi
P
P
Sabbioni
S
S
Caputo
A
A
Balboni
P G
PG
Gualandri
R
R
Manservigi
R
R
Grossi
M P
MP
Barbanti-Brodano
G
G
D017456:Adenovirus Early Proteins; D002461:Cell Line, Transformed; D015500:Chloramphenicol O-Acetyltransferase / Q000235:genetics; D003001:Cloning, Molecular; D004247:DNA / Q000235:genetics*; D015870:Gene Expression; D015696:Gene Products, tat / Q000096:biosynthesis* / Q000235:genetics; D005822:Genetic Vectors; D016325:HIV Long Terminal Repeat / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics*; D006514:Hepatitis B Surface Antigens / Q000235:genetics; D006801:Humans; D009693:Nucleic Acid Hybridization; D009856:Oncogene Proteins, Viral / Q000096:biosynthesis* / Q000235:genetics; D010957:Plasmids; D015183:Restriction Mapping; D015533:Transcriptional Activation; D014162:Transfection; D054322:tat Gene Products, Human Immunodeficiency Virus
D017456:Adenovirus Early Proteins; D015696:Gene Products, tat; D006514:Hepatitis B Surface Antigens; D009856:Oncogene Proteins, Viral; D054322:tat Gene Products, Human Immunodeficiency Virus; D004247:DNA; D015500:Chloramphenicol O-Acetyltransferase